Advertisement
Advertisement
U.S. markets close in 3 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (JAM1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.0345+0.0036 (+11.65%)
As of 08:01AM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0309
Open0.0308
Bid0.0310 x 4074100
Ask0.0597 x 2558200
Day's Range0.0345 - 0.0345
52 Week Range0.0300 - 0.2755
Volume676
Avg. Volume353
Market Cap20.552M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-0.0810
Earnings DateApr 13, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for JAM1.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • CNW Group

      Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development in collaboration with Panag, a subsidiary of Tetra Bio-Pharma, and True North Cannabis Corp (True North), today announced it has entered into a technology licensing agreement allowing True North to use its highly innovative proprietary liposome encapsulated technology within formulations distributed under the True North brand.

    • PR Newswire

      Tetra Bio-Pharma and Cannvalate Enter Into Partnership

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development, today announced it has entered into a research and development agreement with Cannvalate Pty Ltd ("Cannvalate") for the initiation of the REBORN®, PLENITUDE® and CAUMZ® clinical trials in Australia, and a subscription agreement contemplating a private placement (the "Private Placement") of common shares in the capital of the Company (the "Common Sh

    • CNW Group

      Tetra Bio-Pharma's QIXLEEF™ on Track After Type C Meeting with U.S. FDA

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for its inhaled cannabinoid-based product, QIXLEEF™. The meeting was held to discuss the nonclinical safety requirements for the marketing approval.

    Advertisement
    Advertisement